Font: Financial Modeling Prep • May 28, 2026
Build-A-Bear Workshop is a global retailer offering an interactive experience where customers create their own personalized stuffed animals. The company recently announced its first-quarter fiscal 2026 financial results, which presented a mixed picture when compared to what market analysts were expecting.
The company reported strong profitability with a diluted earnings per share (EPS) of $1.45. This figure is an increase from the $1.17 reported in the same quarter of the previous year. Additionally, its adjusted EPS of $1.03 significantly beat the analyst consensus estimate of $0.76, as highlighted by Zacks.
On the other hand, Build-A-Bear Workshop's quarterly revenue of $125.27 million did not meet the analyst consensus estimate of $129.45 million. This revenue figure also marks a slight decrease from the $128.4 million reported a year ago. As reported by Business Wire, the company attributes this to a "more uncertain economic environment."
From a valuation standpoint, Build-A-Bear Workshop has a Price-to-Earnings (P/E) ratio of 8.41. This ratio shows how much investors are willing to pay for each dollar of the company's earnings. Its Price-to-Sales (P/S) ratio stands at 0.88, comparing the stock price to its revenues per share.
The company's financial health appears stable with a current ratio of 1.53, which suggests it can cover its short-term obligations. During the quarter, Build-A-Bear Workshop also returned $14.2 million to its shareholders through a combination of share repurchases and dividends, showing a commitment to providing shareholder value.
|
VNRX§>
VolitionRX Ltd
|
$0.50
47.70%
|
|
NVDA§>
NVIDIA Corporation
|
$227.98
8.74%
|
|
RITR§>
Reitar Logtech Holdings Limited Ordinary shares
|
$0.10
11.75%
|
|
CELU§>
Celularity Inc.
|
$2.10
138.53%
|
|
NVD§>
GraniteShares 2x Short NVDA Daily ETF
|
$3.73
-16.93%
|
|
WKSP§>
Worksport Ltd.
|
$0.63
23.53%
|
|
MERC§>
Mercer International Inc.
|
$0.39
-5.57%
|
|
INTC§>
Intel Corp.
|
$92.09
4.36%
|
|
NCPL§>
Netcapital Inc.
|
$0.54
7.55%
|
|
PPCB§>
Propanc Biopharma, Inc.
|
$2.23
108.41%
|